Business Wire

Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy

Jaa

Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced the winner of the tomy’s (Teva’s Orphan hematological Malignancies award for Young hematologists) at the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy last week. During the event entitled, ‘Next-Generation APL Leaders: Teva’s Award for Young Hematologists’ Dr. Salamero was awarded a tomy’s trophy, as well as a bursary to attend the 2017 American Society of Hematology (ASH) Annual Meeting, taking place in the USA in December.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171005005748/en/

Dr. Olga Salamero presenting her research during the Next-Generation APL Leaders Teva’s Award for Yo ...

Dr. Olga Salamero presenting her research during the Next-Generation APL Leaders Teva’s Award for Young Hematologists in Rome, Italy (Photo: Business Wire)

Dr. Salamero is currently a hematologist at the Vall d’Hebron University Hospital, Barcelona, Spain and presented research entitled Very elderly acute promyelocytic leukemia: a multicentric experience. The study selected patients aged ≥ 75 years old with APL who had reported to PETHEMA registry (Spanish Hematology Treatment Programme) over the last nineteen years. Epidemiologic characteristics and disease features in the very elderly APL population were analysed and the percentage of patients treated according to investigators criteria described. The research found that patients treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimen showed better outcomes than patients who received other strategies, such as ATRA alone, chemotherapy alone or best supportive care.

Speaking after the awards ceremony, Dr. Salamero said, “Winning the tomy’s - it’s been a pleasure. I feel proud, not because of my work but the work of the PETHEMA group. I would recommend attending the APL Symposium as not only is it very interesting, but it facilitates a lot and keeps you in touch with your peers.”

The tomy’s are an educational award programme for young hematologists, sponsored by Teva Oncology. The awards are open to young hematologists, or young physicians training to become hematologists aged 40 years or younger. The entrants are challenged to illustrate the latest scientific advancements in the management of orphan hematological malignancies by presenting a case study or case series demonstrating their excellence in education and presentation skills. The independent jury for the 2017 tomy’s was comprised of experts in orphan hematological malignancies and includes Pierre Fenaux, France; Richard Schlenk, Germany; Francesco Lo-Coco, Italy; Bob Löwenberg, Netherlands; Nigel Russell, UK and Miguel Sanz, Spain.

“It’s estimated that between 1,500 – 2,000 people in Europe are diagnosed with APL each year. Even though APL is the most lethal type of acute leukemia, it’s highly curable and more research into this disorder is urgently needed. The tomy’s programme reflects Teva’s commitment to encouraging new and innovative research aimed at improving patient outcomes in orphan hematological malignancies,” said Paul Harmon, Head of Teva’s Oncology Care and Transplant Europe.

“APL can cause a number of symptoms including uncontrollable bleeding and can kill within hours or days if left untreated. As it’s so rare, APL can be difficult to recognise and diagnose. We’re excited about this programme, and we believe it will stimulate new exciting research, with the ultimate ambition of saving lives,” commented Prof. Lo-Coco, tomy jury member.

The full list of finalists as well as more information on the jury can be accessed via: https://www.thinkapl.com/jury/

The tomy’s awards ceremony in Rome follows the inaugural tomy’s awards, announced at the Teva Oncology Satellite Symposium at the Acute Leukemias XVI International Symposium, which took place in Munich, Germany, in February 2017.

For more information on the Tomy’s awards or for queries regarding abstract submissions or notifications, please contact: support@oncotomys.com.

-ENDS-

About Teva

Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

Contact information

Teva
Fiona Cohen
+31 6 2008 2545
or
Jayson Otke
+31 6 8201 5407

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)22.9.2018 01:13Tiedote

Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced

Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 20:43Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar

Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 19:41Tiedote

Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo

Florian Winterstein Becomes New CEO of Jedox21.9.2018 18:46Tiedote

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it

Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter21.9.2018 17:37Tiedote

Since 2010 Avinor has had a vision and a desire to automate winter maintenance. In March autonomous snow clearing was demonstrated at Fagernes Airport, and this winter Avinor is taking this a step further by testing two autonomous snowploughs at Oslo Airport. The project is one of the first globally where large machinery will operate autonomously to keep snow away from airport areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005363/en/ Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter (Photo: Business Wire) “Innovation is important to Avinor. In the future, many tasks in aviation will be resolved in other ways than today. Avinor wants to test autonomy, and does of course see a potential for rationalization in the future through new solutions for winter operations and in other areas. Avinor is at the forefront of testing this technology, but it is essential that safety is ensured in all such testing

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 16:30Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme